Palbociclib and Pembrolizumab in Sarcoma
Phase 1
8
about 4.5 years
12+
1 site in IA
What this study is about
Researchers are testing the impact of palbociclib as a treatment for soft tissue sarcomas. It involves giving palbociclib before pembrolizumab, which is an approved PD-1 inhibitor. The trial will last approximately 1642 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Palbociclib
- 2.Take Pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
palbociclib, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
oral (Oral Capsule), infusion
Primary: Dose limiting toxicities (DLTs) and adverse events (AEs) per CTCAE v5
Secondary: Response rate per RECIST 1.1 criteria